Excess Costs and Economic Burden of Obesity-Related Cancers in the United States.
cancer burden in the United States
economic burden of cancer
excess costs of cancer care
obesity-related cancer
Journal
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
14
02
2019
revised:
03
07
2019
accepted:
14
07
2019
entrez:
7
12
2019
pubmed:
7
12
2019
medline:
6
6
2020
Statut:
ppublish
Résumé
Obesity is a significant risk factor of several cancers that imposes a substantial economic burden on US healthcare that remains to be quantified. We estimated the excess costs and economic burden of obesity-related cancers in the United States. From the Medical Expenditure Panel Survey (2008-2015) data, we identified 19 405 cancer survivors and 175 498 non-cancer individuals. We estimated annual health expenditures using generalized linear regression with log link and gamma distribution by cancer types (stratified by 11 obesity-related cancers and other cancer types), controlling for sociodemographic and clinical characteristics. All cost estimates were adjusted to 2015 USD value. The average annual total health expenditures were $21 503 (95% CI, $20 946-$22 061) for those with obesity-related cancer and $13 120 (95% CI, $12 920-$13 319) for those with other cancer types. There was a positive association between body mass index and health expenditures among cancer survivors: for each additional 5-unit increase in body mass index, the average predicted expenditures increase by $1503 among those with obesity-related cancer and by $722 among those with other cancers. With adjustments for sociodemographic and clinical characteristics, the mean incremental expenditures of treating obesity-related cancer were 2.1 times higher than those of other cancers ($4492 vs $2139) and more considerable among the non-elderly cancer population. Obesity-related cancers accounted for nearly 43.5% of total direct cancer care expenditures, estimated at $35.9 billion in 2015. The economic burden of obesity-related cancer in the United States is substantial. Our findings suggest a need for the inclusion of comprehensive obesity prevention and treatment in cancer care.
Sections du résumé
BACKGROUND
Obesity is a significant risk factor of several cancers that imposes a substantial economic burden on US healthcare that remains to be quantified. We estimated the excess costs and economic burden of obesity-related cancers in the United States.
METHODS
From the Medical Expenditure Panel Survey (2008-2015) data, we identified 19 405 cancer survivors and 175 498 non-cancer individuals. We estimated annual health expenditures using generalized linear regression with log link and gamma distribution by cancer types (stratified by 11 obesity-related cancers and other cancer types), controlling for sociodemographic and clinical characteristics. All cost estimates were adjusted to 2015 USD value.
RESULTS
The average annual total health expenditures were $21 503 (95% CI, $20 946-$22 061) for those with obesity-related cancer and $13 120 (95% CI, $12 920-$13 319) for those with other cancer types. There was a positive association between body mass index and health expenditures among cancer survivors: for each additional 5-unit increase in body mass index, the average predicted expenditures increase by $1503 among those with obesity-related cancer and by $722 among those with other cancers. With adjustments for sociodemographic and clinical characteristics, the mean incremental expenditures of treating obesity-related cancer were 2.1 times higher than those of other cancers ($4492 vs $2139) and more considerable among the non-elderly cancer population. Obesity-related cancers accounted for nearly 43.5% of total direct cancer care expenditures, estimated at $35.9 billion in 2015.
CONCLUSION
The economic burden of obesity-related cancer in the United States is substantial. Our findings suggest a need for the inclusion of comprehensive obesity prevention and treatment in cancer care.
Identifiants
pubmed: 31806194
pii: S1098-3015(19)32266-1
doi: 10.1016/j.jval.2019.07.004
pmc: PMC7313233
mid: NIHMS1594609
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1378-1386Subventions
Organisme : NHLBI NIH HHS
ID : K01 HL141535
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier Inc.
Références
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Ann Intern Med. 2017 Mar 21;166(6):381-389
pubmed: 28166546
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Obesity (Silver Spring). 2017 Nov;25 Suppl 2:S27-S29
pubmed: 29086512
Med Care. 2009 Jul;47(7 Suppl 1):S44-50
pubmed: 19536015
Am J Clin Oncol. 2018 Feb;41(2):121-127
pubmed: 26523440
JAMA Surg. 2015 Jan;150(1):17-22
pubmed: 25372703
J Gerontol A Biol Sci Med Sci. 2005 Sep;60(9):1184-9
pubmed: 16183961
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1244-59
pubmed: 22695735
Nat Rev Clin Oncol. 2013 Feb;10(2):90-9
pubmed: 23207794
Lancet. 2011 Mar 26;377(9771):1085-95
pubmed: 21397319
J Oncol Pract. 2012 Nov;8(6):75s-80s
pubmed: 23598848
J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):1-5
pubmed: 21475699
Obesity (Silver Spring). 2017 Nov;25 Suppl 2:S9-S22
pubmed: 29086526
J Natl Cancer Inst. 2007 Jan 3;99(1):14-23
pubmed: 17202109
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
JAMA. 2007 Nov 7;298(17):2028-37
pubmed: 17986696
JAMA. 2018 Apr 24;319(16):1723-1725
pubmed: 29570750
MMWR Morb Mortal Wkly Rep. 2017 Oct 03;66(39):1052-1058
pubmed: 28981482
J Clin Oncol. 2013 Oct 20;31(30):3749-57
pubmed: 24043731
Lancet Public Health. 2019 Mar;4(3):e137-e147
pubmed: 30733056
Cancer Med. 2016 Apr;5(4):665-75
pubmed: 26811258
Annu Rev Public Health. 2018 Apr 1;39:489-505
pubmed: 29328879
Cancer. 2015 Sep 15;121(18):3272-80
pubmed: 26042576
Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1695-8
pubmed: 19505901